Swine Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Attenuated Live Vaccines, DNA Vaccines, Inactivated Vaccines, Recombinant Vaccines, Subunit Vaccines), By Type (Actinobacillus Pleuropneumoniae, Classical Swine Fever, Foot & Mouth Disease, PEDV, Porcine Circovirus Type 2, Porcine Parvovirus, PRRS, Pseudorabies, Swine Influenza), By Target Disease (Arthritis, Bordetella Rhinitis, Diarrhea, Foot & Mouth Disease, Porcine Circovirus Associated Disease, Porcine Reproductive & Respiratory Syndrome, Pseudorabies, Swine Influenza), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.39 Billion
CAGR (2026-2031)	4.88%
Fastest Growing Segment	Recombinant Vaccines
Largest Market	Asia Pacific
Market Size (2031)	USD 1.85 Billion

Market Overview

The Global Swine Vaccines Market will grow from USD 1.39 Billion in 2025 to USD 1.85 Billion by 2031 at a 4.88% CAGR. Swine vaccines are biological preparations formulated to stimulate the immune system of pigs and provide acquired immunity against specific pathogens. The primary drivers fueling the growth of this market include the escalating global consumption of pork which necessitates efficient livestock production and the implementation of stringent food safety regulations to control zoonotic risks. Furthermore, the increasing emphasis on preventative veterinary care to minimize financial losses associated with disease outbreaks significantly bolsters the demand for these immunization products.

According to the Agriculture and Horticulture Development Board, in 2025, global pork production was forecast to reach 116.7 million metric tons. This substantial production volume indicates a vast addressable market for veterinary health products to ensure herd sustainability. However, a significant impediment to market expansion is the high cost and logistical complexity associated with maintaining the cold chain infrastructure required for the effective storage and distribution of these sensitive biological products in emerging economies.

Key Market Drivers

The increasing prevalence of transboundary and zoonotic swine diseases acts as the primary catalyst propelling the global swine vaccines market. The persistent spread of high-impact pathogens, such as African Swine Fever (ASF) and Porcine Reproductive and Respiratory Syndrome (PRRS), compels producers to adopt rigorous immunization schedules to safeguard herd health and economic viability. These outbreaks not only disrupt international trade but also threaten food security, necessitating immediate veterinary intervention to prevent catastrophic stock depletion. For instance, according to the World Organisation for Animal Health, November 2025, in its Situation Report, African Swine Fever had been reported in 71 countries since January 2022, causing over 2.2 million animal losses. Such widespread devastation underscores the critical reliance on prophylactic measures, driving sustained demand for effective biological countermeasures across major pork-producing regions.

Escalating R&D investments for novel and evolving viral strains further accelerate market development, as pharmaceutical companies race to address gaps in immunity and vaccine efficacy. To combat emerging variants and improve delivery mechanisms, industry leaders are channeling significant capital into expanding manufacturing infrastructure and scientific capabilities. According to Feed and Additive, May 2025, Merck Animal Health announced an $895 million expansion in Kansas specifically to boost vaccine manufacturing and research capabilities. This surge in funding facilitates the creation of next-generation solutions, although commercial success remains closely tied to the market uptake of these advanced biologicals. Illustrating the substantial economic scale of established immunization products, according to Boehringer Ingelheim, in April 2025, the annual sales of its Ingelvac Circoflex swine vaccine reached 215 million EUR for the 2024 financial year. These investments and commercial returns highlight the sector's robust financial commitment to advancing porcine health technologies.

Download Free Sample Report

Key Market Challenges

The high cost and logistical complexity of maintaining cold chain infrastructure significantly impedes the expansion of the Global Swine Vaccines Market, particularly within emerging economies. Swine vaccines are strictly temperature-sensitive biological products that require an unbroken chain of climate-controlled storage from manufacturing to administration. In developing regions where pork production is intensifying, the absence of reliable electricity and specialized logistics networks forces distributors to incur exorbitant expenses to prevent product spoilage. This financial burden inflates the final cost of immunization, making essential veterinary care economically inaccessible for many small-scale farmers who constitute a crucial segment of the addressable market.

Consequently, this logistical bottleneck restricts market penetration in high-growth geographic zones, effectively stalling revenue generation despite the urgent need for disease control. The inability to deliver viable vaccines reliably correlates with sustained productivity losses that the market is struggling to mitigate. According to the Food and Agriculture Organization, in 2024, transboundary animal diseases were estimated to cause global economic losses of approximately USD 300 billion annually, representing a roughly 20 percent loss in total livestock production value. This data highlights the substantial market gap where infrastructure deficits prevent the effective delivery of immunization products, thereby hampering the industry's ability to capitalize on global demand.

Key Market Trends

Accelerated R&D for African Swine Fever Solutions is rapidly transitioning from experimental trials to the commercial deployment of viable immunizations, fundamentally altering disease management protocols in endemic regions. While biosecurity remains foundational, the market is witnessing the historic introduction of approved biological countermeasures entering international trade, driven by the urgent need to protect standing herds in Southeast Asia. This shift validates the scientific community's focus on live attenuated platforms to combat complex viral threats that previously lacked effective prophylaxis. For instance, demonstrating this growing cross-border trust in new formulations, according to VietnamPlus, September 2025, the AVAC Vietnam Joint Stock Company exported a second batch comprising 340,000 doses of its African Swine Fever vaccine to the Philippines to support the country’s disease control efforts.

Simultaneously, the Development of Multivalent and Combination Vaccines is reshaping herd health strategies by prioritizing operational efficiency and animal welfare through reduced handling. Producers are increasingly adopting multi-antigen formulations that allow for simultaneous protection against diverse pathogens or multiple viral genotypes in a single administration, thereby minimizing stress-induced performance dips and lowering labor costs. This trend is compelling manufacturers to integrate broader coverage into their flagship product lines to match the evolving genetic diversity of field strains. Illustrating this advancement, according to National Hog Farmer, September 2025, Boehringer Ingelheim launched Ingelvac Circoflex AD, a novel combination vaccine specifically engineered to target the PCV2a and PCV2d genotypes responsible for over 90 percent of clinical porcine circovirus cases.

Segmental Insights

Recombinant vaccines constitute the fastest-growing segment within the global swine vaccines market, primarily due to their favorable safety profile and ability to distinguish vaccinated animals from infected ones. This specific capability allows producers to participate in disease eradication programs without the risks of reversion to virulence associated with conventional modified live options. Regulatory bodies such as the United States Department of Agriculture actively support these technologies for managing complex viral threats. Consequently, the rising demand for effective solutions against porcine reproductive and respiratory syndrome fuels substantial market expansion.

Regional Insights

Asia Pacific dominates the Global Swine Vaccines Market, primarily driven by the region's extensive swine inventory and the critical need for disease management solutions. China, widely recognized as the world’s largest pork producer, anchors this market leadership through its vast commercial farming operations. The region faces persistent challenges from high-impact outbreaks such as African Swine Fever and Porcine Reproductive and Respiratory Syndrome, which necessitate rigorous immunization schedules. Consequently, institutions like China’s Ministry of Agriculture and Rural Affairs have enforced stricter biosecurity mandates and vaccination protocols to safeguard herd health, ensuring sustained market expansion amidst rising pork consumption.

Recent Developments

• In September 2025, Boehringer Ingelheim launched a new swine vaccine in the United States that combines antigens for two genotypes of Porcine Circovirus type 2 (PCV2a and PCV2d) into a single dose. This product was developed to provide broad protection against the most prevalent PCV2 genotypes responsible for clinical cases of porcine circovirus-associated disease. The vaccine is approved for use in pigs as young as two weeks of age and offers an immunity duration of at least six months. The release of this dual-antigen vaccine addresses the market's need for updated tools to manage evolving viral threats and reduce the impact of co-infections.
• In July 2025, Virbac launched two complementary oral vaccines in Thailand aimed at preventing post-weaning diarrhea and edema disease in piglets. These products target the F4 and F18 adhesion factors of Escherichia coli, which are primary bacterial causes of these conditions in the region. The launch was presented as a strategic move to replace traditional antibiotic treatments with preventive biological solutions, thereby addressing industry concerns regarding antimicrobial resistance. The company emphasized that these vaccines can be administered separately or in combination, offering farmers flexibility in supporting the digestive health of piglets during the critical weaning phase.
• In October 2024, Ceva Animal Health received marketing authorization from the European Commission for a new ready-to-use vaccine formulated to protect pigs against Porcine Circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae. The vaccine incorporates the PCV2d genotype, which the company identified as the most circulating genotype in the field, along with a specific strain of the respiratory pathogen. A single injection was approved to provide protection from six weeks of age through the entire fattening period. This development offers producers a consolidated method to improve respiratory health and effectively manage the Porcine Respiratory Diseases Complex in commercial operations.
• In March 2024, Merck Animal Health announced that it received license approval from the U.S. Department of Agriculture (USDA) for a new prescription vaccine designed for use in gilts and sows. The product utilizes an RNA particle technology platform combined with a proprietary adjuvant to create precise immunological solutions tailored to specific herd needs. This platform enables the rapid development of targeted vaccines for evolving viral and bacterial pathogens in swine, such as influenza and rotavirus. The company noted that this technology significantly reduces development timelines compared to traditional vaccine production methods, providing a flexible tool for veterinarians to address herd-specific challenges.

Key Market Players

• Merck & Co Inc
• Zoetis Inc
• Boehringer Ingelheim GmbH
• Elanco Animal Health Inc
• Indian Immunologicals Ltd
• Biogénesis Bagó SA
• Phibro Animal Health Corp
• Laboratorios HIPRA SA
• Virbac SA

By Product	By Type	By Target Disease	By Region
Attenuated Live Vaccines DNA Vaccines Inactivated Vaccines Recombinant Vaccines Subunit Vaccines	Actinobacillus Pleuropneumoniae Classical Swine Fever Foot & Mouth Disease PEDV Porcine Circovirus Type 2 Porcine Parvovirus PRRS Pseudorabies Swine Influenza	Arthritis Bordetella Rhinitis Diarrhea Foot & Mouth Disease Porcine Circovirus Associated Disease Porcine Reproductive & Respiratory Syndrome Pseudorabies Swine Influenza	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Swine Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Swine Vaccines Market, By Product:

• Attenuated Live Vaccines
• DNA Vaccines
• Inactivated Vaccines
• Recombinant Vaccines
• Subunit Vaccines

• Swine Vaccines Market, By Type:

• Actinobacillus Pleuropneumoniae
• Classical Swine Fever
• Foot & Mouth Disease
• PEDV
• Porcine Circovirus Type 2
• Porcine Parvovirus
• PRRS
• Pseudorabies
• Swine Influenza

• Swine Vaccines Market, By Target Disease:

• Arthritis
• Bordetella Rhinitis
• Diarrhea
• Foot & Mouth Disease
• Porcine Circovirus Associated Disease
• Porcine Reproductive & Respiratory Syndrome
• Pseudorabies
• Swine Influenza

• Swine Vaccines Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE